Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Finished Goods (2021 - 2023)

Historic Finished Goods for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Q4 2023 value amounting to $12.9 million.

  • Kiniksa Pharmaceuticals International's Finished Goods fell 1585.01% to $12.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $12.9 million, marking a year-over-year decrease of 1585.01%. This contributed to the annual value of $12.9 million for FY2023, which is 1585.01% down from last year.
  • Kiniksa Pharmaceuticals International's Finished Goods amounted to $12.9 million in Q4 2023, which was down 1585.01% from $12.2 million recorded in Q3 2023.
  • Kiniksa Pharmaceuticals International's Finished Goods' 5-year high stood at $19.9 million during Q2 2022, with a 5-year trough of $1.4 million in Q3 2021.
  • Its 3-year average for Finished Goods is $10.4 million, with a median of $12.5 million in 2023.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Finished Goods skyrocketed by 92747.72% in 2022 and then crashed by 2422.18% in 2023.
  • Kiniksa Pharmaceuticals International's Finished Goods (Quarter) stood at $3.7 million in 2021, then surged by 315.97% to $15.3 million in 2022, then decreased by 15.85% to $12.9 million in 2023.
  • Its Finished Goods stands at $12.9 million for Q4 2023, versus $12.2 million for Q3 2023 and $17.3 million for Q2 2023.